Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Y90 radioembolization
DEVICE
2 trials
Sponsors
Ashwin Somasundaram
, Northwestern University
Conditions
Adult Primary Liver Cancer
HCC
Hepatocellular Carcinoma
Metastatic Cancer
Resection
Transplant
Early Phase 1
Pembrolizumab Plus Y90 Radioembolization in HCC Subjects
NCT03099564
Ashwin Somasundaram
Hepatocellular Carcinoma
Start: 2017-03-28
End: 2023-06-30
Target: 30
Updated: 2023-02-06
Unknown Phase
Optimizing Y90 Therapy for Radiation Lobectomy
Active, not recruiting
NCT04390724
Northwestern University
Adult Primary Liver Cancer, HCC, Metastatic Cancer +2
Start: 2020-07-17
End: 2026-11-27
Updated: 2026-09-16
Related Papers
A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma
UNC Libraries
2024-10-16
A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma
The Oncologist
2024-02-07
34 citations
A study of pembrolizumab (pembro) in combination with Y90 radioembolization in patients (pts) with poor prognosis hepatocellular carcinoma (HCC).
Journal of Clinical Oncology
2023-01-24
4 citations
A study of pembrolizumab (pembro) in combination with Y90 radioembolization in patients (pts) with poor prognosis hepatocellular carcinoma (HCC) with preserved liver function.
Journal of Clinical Oncology
2022-01-19
8 citations